Oxytocin improves treatment of obstructive sleep apnea
US-10166268-B2 · Jan 1, 2019 · US
Oxytocin improves treatment of obstructive sleep apnea
US10842845B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10842845-B2 |
| Application number | US-201816184091-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 8, 2018 |
| Priority date | Jul 25, 2014 |
| Publication date | Nov 24, 2020 |
| Grant date | Nov 24, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides methods for treating obstructive sleep apnea (OSA) and OSA induced cardiorespiratory diseases. The disclosure provides, inter alia, methods for treating or alleviating: OSA or OSA induced hypertension, cardiac arrhythmias, myocardial ischemia, sudden cardiac death or stroke, by administering oxytocin. The disclosure further provides methods for improving sleep satisfaction in OSA patients by administering oxytocin.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for improving sleep quality in a patient suffering from obstructive sleep apnea, comprising: intranasally administering to the patient at least 40 International Units (IU) of oxytocin within an hour of the patient falling asleep, wherein the administration of oxytocin decreases the number of arousals per hour experienced by the patient during sleep. 2. The method of claim 1 , wherein the administration of oxytocin decreases the number of arousals per hour by at least 10%. 3. The method of claim 1 , wherein the patient is receiving continuous positive airway pressure (CPAP) therapy. 4. The method of claim 1 , wherein the administration of oxytocin leads to improvement in empirical factors indicative of sleep quality in the patient. 5. The method of claim 1 , wherein the administration of oxytocin leads to a decrease in the duration of apnea experienced by the patient during sleep. 6. The method of claim 5 , wherein the administration of oxytocin decreases the duration of apnea by at least 10%. 7. The method of claim 1 , wherein the administration of oxytocin decreases the oxygen desaturation experienced by the patient during sleep. 8. The method of claim 1 , wherein the administration of oxytocin maintains or decreases the heart rate and/or blood pressure of the patient. 9. A method for treating obstructive sleep apnea in a patient receiving continuous positive airway pressure (CPAP) therapy, comprising: administering to the patient at least 40 International Units (IU) of oxytocin intranasally via the CPAP inhalation system within an hour of the patient falling asleep. 10. The method of claim 9 , wherein the administration of oxytocin decreases the number of arousals per hour experienced by the patient during sleep by at least 10%. 11. The method of claim 9 , wherein the administration of oxytocin leads to a decrease in the duration of apnea experienced by the patient during sleep. 12. The method of claim 11 , wherein the administration of oxytocin decreases the duration of apnea by at least 10%. 13. The method of claim 9 , wherein the administration of oxytocin decreases the oxygen desaturation experienced by the patient during sleep. 14. The method of claim 9 , wherein the administration of oxytocin maintains or decreases the heart rate and/or blood pressure of the patient.
Assignees
Inventors
Classifications
Nose · CPC title
- A61K38/095Primary
Oxytocins; Vasopressins; Related peptides · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10842845B2 cover?
- The present disclosure provides methods for treating obstructive sleep apnea (OSA) and OSA induced cardiorespiratory diseases. The disclosure provides, inter alia, methods for treating or alleviating: OSA or OSA induced hypertension, cardiac arrhythmias, myocardial ischemia, sudden cardiac death or stroke, by administering oxytocin. The disclosure further provides methods for improving sleep sa…
- Who is the assignee on this patent?
- Univ George Washington
- What technology area does this patent fall under?
- Primary CPC classification A61K38/095. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).